EGFR and cancer: Cetuximab–SNS-032 ADC inhibited the cell cycle, restricted cellular growth and viability, exerted bystander killing effects on local EGFR-low cancer cells, and despite carrying a small fraction of the inhibitor dose needed to exert antitumor effects, the ADC inhibited orthotopic TNBC xenograft growth in vivo.